Epoch Investment Partners Inc. Purchases 21,881 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Epoch Investment Partners Inc. boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 5.3% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 438,100 shares of the company's stock after buying an additional 21,881 shares during the period. Epoch Investment Partners Inc. owned approximately 1.41% of Medpace worth $145,550,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Lindbrook Capital LLC grew its holdings in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares in the last quarter. HBK Sorce Advisory LLC boosted its holdings in Medpace by 0.5% in the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after purchasing an additional 29 shares during the last quarter. Assetmark Inc. grew its stake in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares in the last quarter. Proficio Capital Partners LLC increased its holdings in Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after purchasing an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. boosted its stake in shares of Medpace by 1.2% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after buying an additional 30 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Up 3.8 %

Medpace stock traded up $11.18 during mid-day trading on Thursday, hitting $301.72. 277,578 shares of the company's stock traded hands, compared to its average volume of 338,036. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $459.77. The firm has a 50 day moving average price of $315.38 and a 200 day moving average price of $332.24. The company has a market cap of $9.12 billion, a PE ratio of 23.84, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter last year, the company earned $3.20 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Leerink Partnrs raised Medpace to a "hold" rating in a report on Monday, March 24th. Truist Financial lowered their price target on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday. Robert W. Baird reduced their price objective on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday. Finally, TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and lowered their target price for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Medpace has an average rating of "Hold" and a consensus price target of $349.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.